Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
TBPH
TBPH
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TBPH News
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
Jan 20 2026
NASDAQ.COM
Cyclerion Therapeutics Expands Collaboration with Medsteer, Shares Surge 44.2%
Jan 06 2026
Benzinga
mF International Files Mixed Shelf, Shares Drop 4.6%
Jan 05 2026
Benzinga
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
Jan 05 2026
Benzinga
Shifts in the Narrative Surrounding Theravance Biopharma Following Trelegy Monetization and Strategic Review
Dec 12 2025
Yahoo Finance
Theravance Biopharma (TBPH) Shows Strong Momentum: Is It a Good Investment?
Dec 08 2025
NASDAQ.COM
Three Stocks Poised for Significant Gains, According to Top Analysts – 11/28/2025
Nov 28 2025
TipRanks
Broadcom Set to Surge by 13%? Check Out 10 Leading Analyst Predictions for Wednesday
Nov 26 2025
Benzinga
BTIG Reaffirms Buy Rating for Theravance Biopharma, Increases Price Target to $40
Nov 26 2025
Benzinga
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
Nov 20 2025
PRnewswire
Theravance Biopharma to Participate in Upcoming Investor Conferences
Nov 19 2025
PRnewswire
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 10 2025
PRnewswire
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
Oct 29 2025
PRnewswire
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
Oct 27 2025
PRnewswire
Protagonist Therapeutics Analyst Starts Coverage Optimistically; Check Out the Top 3 Initiations for Friday
Sep 12 2025
Benzinga
B. Riley Securities Begins Coverage of Theravance Biopharma with a Buy Rating and Sets Price Target at $28
Sep 12 2025
Benzinga
Show More News
